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Phenols are uremic toxins of intestinal origin formed by bacteria during protein metabolism. Of these molecules, p-cresol is the
most studied and has been associated with renal function impairment and vascular damage. Bisphenol A (BPA) is a molecule with
structural similarity with phenols found in plastic food and beverage containers as well as in some dialyzers. BPA is considered
an environmental toxicant based on animal and cell culture studies. Japanese authorities recently banned BPA use in baby bottles
based on observational association studies in newborns. BPA is excreted in urine and uremic patients present higher serum levels,
but there is insufficient evidence to set cut-off levels or to link BPA to any harmful effect in CKD. However, the renal elimination
and potential exposure during dialysis warrant the monitoring of BPA exposure and the design of observational studies in which
the potential health risks of BPA for end-stage renal disease patients are evaluated.
1. Uremic Toxins
Multiple molecules accumulate in chronic kidney disease
(CKD), are responsible for uremic symptoms, and contribute
to increased mortality (uremic toxins). Removal of uremic
toxins therefore is accompanied by an improvement in the
clinical situation. The term of uremic toxin was created
by Piorry in 1847 to indicate the “blood contamination
with urine” to refer to the signs and symptoms resulting
from kidney disease that increase mortality. Bergstrom [1]
proposed that a uremic toxin should be defined as one
molecule that meets the following premises:
(1) the chemical identity and concentration in biological
fluids should be known,
(2) the concentration in uremic individuals should be
higher than in nonuremic subjects,
(3) the concentration should correlatewith uremic symp-
toms, and symptoms should disappear by decreasing
the concentration.
Uremic toxins have been classified according to size [2].
Over 350 small uremic toxins have been described with a
molecular weight below 500Da [3].Medium-sizedmolecules
have a molecular weight between 500 and 5000Da. Many
uremic toxins are bound to proteins which hamper their
clearance.
Uremic toxins are responsible for uremic disease. Among
the changes that have been directly related to uremic toxins
we find progressive loss of renal function, cardiovascular
morbidity, and uremic symptoms such as anorexia, vomiting,
weakness, sleep disturbances, and neuropathy.
The origin of uremic toxins is multiple. Most uremic
toxins originate from the endogenous cellular metabolism.
However, there is a growing list of uremic toxins originated






























Figure 1: Chemical structures. (a) Bisphenol A (BPA), (b) BPA-
containing polycarbonatemonomer, (c) p-cresol, (d) p-cresyl sulfate
(e) p-cresyl sulfate glucuronide, (f) phenol, and (g) phenylacetic
acid.
in the intestinalmicrobiota [4].The diet and the environment
may also be sources of uremic toxins [5].
Uremic toxins accumulate progressively as kidney func-
tion decreases. There are therapeutic approaches to lower the
levels of certain uremic toxins in CKD, such as the use of
phosphate binders. Once end-stage renal disease is reached,
dialysis contributes to clearance of molecules <50,000Da.
Clearance of small molecules like urea (60Da) or creatinine
(113Da) depends mainly on diffusion, so they are cleared
efficiently by any dialysis membrane or technique. However,
medium and large molecules are better cleared by techniques
providing high convective transport.
2. Protein-Bound Uremic Toxins
A 2008 review found 115 protein-bound uremic toxins [2].
Protein binding impairs dialysis clearance, regardless of its
molecular weight [6]. Online hemodiafiltration with reinfu-
sion of ultrafiltrate is the technique that better clears protein-
bound toxins [7].
In addition albumin-bound toxins may be taken up by
albumin receptors, thus facilitating access into the celland
toxicity. Furthermore toxin binding to albumin competes
with binding of other molecules typically carried by albumin,
interfering with their distribution and metabolism. As an
example albumin-bound uremic toxins can increase toxicity
of anionic drugs and endogenousmolecules such as bilirubin.
3. Phenols and Indoles
Phenols and indoles are the best-characterized protein-
bound uremic toxins. Both have been related to progression
of renal failure and to vascular damage. These toxins are
metabolites of protein catabolism by intestinal bacteria,
which is greatly increased in patients with CKD. Dietary pro-
teins and peptides are degraded by proteases and peptidases
to amino acids. A part of the amino acids reach the colon
where they are degraded by intestinal bacteria generating
potentially toxic metabolites such as ammonium, amines,
thiols, phenols, and indoles.These products of putrefaction in
the colon are eliminated in feces although some are absorbed
[8].
Among the phenols we must highlight p-cresol and p-
cresyl sulfate, phenyl acetic acid, phenol, and polyamines [9]
(Figure 1).
(i) p-Cresol, p-cresyl sulfate, and p-cresol glucuronide:
p-cresol is a potent oxidant product of themetabolism
of phenylalanine and tyrosine by intestinal anaerobic
bacteria. Most p-cresol is conjugated by the gut
microbiota to p-cresyl sulfate and in the liver to p-
cresylglucuronide. Most p-cresol and p-cresyl sulfate
reache the circulation [10]. Free p-cresol (unbound
to proteins) has been associated to cardiovascular
damage in nondiabetic patients with increased car-
diovascular mortality [11]. However, the method used
to assess p-cresol levels did not distinguish p-cresol
fromconjugated p-cresyl sulfate, and there is evidence
for the toxicity of p-cresyl sulfate [9].
(ii) Phenol comes mainly from the diet, tobacco, and
catabolism of tyrosine and other substrates by intesti-
nal bacteria.
(iii) Phenyl acetic acid results from degradation of pheny-
lalanine and has been associated with impaired
immunoregulation [12], oxidative stress [13], and
osteoblast dysfunction [14].
(iv) Polyamines are a group of organic cations that include
spermine, spermidine, and putrescine, derived from
the catabolism of L-arginine and L-ornithine [15].
These threemolecules are associated with erythropoi-
etin (EPO) resistance. Polyamine-conjugated proteins
accumulate in patients on hemodialysis [16].
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Indoles include indoxyl sulfate and indoleacetic acid
[9]. Indole is an aromatic heterocyclic structure which is
found in many organic compounds such as tryptophan
and its metabolites. Intestinal bacteria produce indole and
indole acetic acid from tryptophan. Indole is subsequently
sulfated to indole sulfate by liver enzymes. These metabolites
accumulate in CKD.
(i) Indoxyl sulphate is a renal and vascular toxin. In
hemodialysis patients indoxyl sulfate levels are asso-
ciated with atherosclerosis [17], endothelial dysfunc-
tion, and vascular calcification [18]. Indoxyl sulphate
has also been implicated in the progression of renal
disease as it may impair cellular antioxidant defenses
and be proinflammatory and profibrotic [19].
(ii) Indoleacetic acid has been associated with progres-
sion of renal interstitial fibrosis [20].
4. Intestinal Uremic Toxins and
Uremic Symptoms
Phenols and indoles have been linked to multiple clinical
changes in CKD patients. These include the following.
(a) Progression of chronic renal failure: both indoxyl
sulphate as p-cresyl sulfate have been associated with
accelerated renal function deterioration [21]. In a
prospective study of 268 patients with CKD both
molecules were predictive of progression of kidney
disease, independently of other cardiovascular risk
factors [22].
(b) Cardiovascular complications: indoxyl sulphate levels
were associated with vascular damage and aortic cal-
cification [23]. Indoxyl sulphate is involved in oxida-
tive stress which promotes proliferation of vascular
smoothmuscle cells [24]. It also increases fibrogenesis
and hypertrophy in cardiac fibroblasts [25].
(c) Anemia: indoxyl sulphate has been linked to renal
anemia by interferingwith erythropoietin production
[26].
(d) Osteodystrophy: indoxyl sulphate promotes oxida-
tive stress and osteoblast resistance to parathormone
(PTH), thus potentially contributing to adynamic
bone [27].
CKD patients have an abnormal intestinal microbiota,
resulting in disrupted fermentation of carbohydrates and
putrefaction of proteins. In hemodialysis patients aero-
bic bacteria such as enterobacteria and enterococcus are
increased and anaerobic bifidobacteria are decreased [28].
Several factors contribute to intestinal dysbacteriosis [8].
(a) Diet: the dialysis patient eats fewer fibers than the
general population, in part due to prescription by
healthcare workers to avoid an overload of potassium.
(b) Constipation: the intestinal transit time increases,
partly due to diet and partly to intestinal dysfunction.
(c) Impaired absorption andmetabolism of proteins, car-
bohydrates, and fats, decreasing the ratio of carbohy-
drate/protein [29]: among the likely causes are bacte-
rial overgrowth and exocrine pancreatic dysfunction
and biliary secretion. Uremia is associated with high
plasma levels of pancreatic secretagogue peptides as
secretin, gastrin, and an abnormal pancreatic juice
compositionwith decreased bicarbonate and amylase.
(d) Alteration of intestinal pH with increased intralumi-
nal ammonia.
(e) Drugs modifying the intestinal microbiota such as
antibiotics and phosphate binders.
5. Decreasing Intestinal Absorption of Indoles
and Phenols in CKD Patients
Evidence available so far suggests that it would be desirable to
maintain low levels of phenols and indoles. In CKD patients
before renal replacement this involves decreasing their syn-
thesis or interferingwith their absorption. Intestinal synthesis
may be decreased by use of probiotics or prebiotics, by
decreasing colon nitrogen and increasing carbohydrates, and
by a diet rich in vegetables and fruits. Probiotics or prebiotics
normalize the intestinal microbiota increasing saccharolytic
and decreasing proteolytic bacteria. Both products reduce
levels of phenols in both healthy individuals and in patients
on hemodialysis [30, 31]. Acarbose reduces the generation of
phenols in colon by increasing carbohydrate availability [32].
A diet rich in vegetables and fruits also reduces the synthesis
of phenols [33], but this diet is not usually used in CKD
patients for the high risk of hyperkalemia. AST-120, an oral
absorbent microsphere, decreased the absorption of p-cresol
[34] and delayed CKD progression [35].
6. Bisphenol A (BPA)
Bisphenol A (BPA) is an environmental toxin containing phe-
nolic rings with structural similarity with phenols (Figure 1).
While the origin of the toxins differs, the metabolism and
side effects of BPA may have common characteristics with
phenols of intestinal origin. BPA is eliminated by the kidney,
and increased blood levels have been observed in CKD.
BPAwas synthesized in the thirties as a synthetic estrogen
[36, 37] but was displaced by diethylstilbestrol. Currently
BPA is used as an additive in plastics and resins. BPA adds
hardness, clarity, lightweight, and resistance to temperature
to polycarbonate plastic and epoxy resins. Polycarbonates
are used in plastic containers commonly used in the food
industry and at home, such as plastic bottles, lenses, and
medical devices. BPA epoxy resins are used as coating in food
and beverage cans. However, due to the potential impact on
health, in Japan epoxy coating was replaced by a polyester
film [38]. BPA is also used in polysulfones and polyether
ketones, as an antioxidant in some plasticizers and as a
polymerization inhibitor in polyvinyl chloride (PVC).
BPA is a chemical switch in endocrine processes, and
may impact reproduction, weight, and development. BPA
acts like a hormone, altering cellular function at very low
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concentrations, with the maximum safe levels of 5mg/kg/day
[39].
BPA may be absorbed in the gastrointestinal tract after
ingesting products packed in plastic containers. Like intesti-
nal phenols, BPA is conjugated by glucuronic acid in bowel
and liver and excreted in urine as BPA-glucuronide [40]
(Figure 2). Exposure may occur by a nonoral route, so it is
considered a toxic environmental origin. Inhalation of BPA
at concentrations > 5.1mg/m3 (0.11 to 0.54 ppm) can cause
coughing and bronchospasm that may persist for several
days. BPA can also cause conjunctivitis, periorbital edema,
skin redness, and roughness.
The EU banned baby bottles with BPA in June 2011 amid
concerns that BPAmay impact neurological and reproductive
development. Studies in animal and cell models have found
these alterations [41–45]. Human data are abundant, but less
consistent, reporting observational associations that cannot
prove causality [46–50]. Certain groups, such as pediatri-
cians, have expressed interest in a primary prevention [46].
However, neither the US Food and Drug Administration
(FDA) nor the EU has found sufficient evidence to ban the
widespread use of BPA in the food and beverage industry
[51]. The FDA has concluded that BPA is safe but in the
absence of conclusive scientific criteria has recommended
reducing exposure as much as possible [52]. BPA has not
been banned on the basis of the following criteria: high cost
of banning its use, high BPA doses used in animal studies,
lack of human interventional studies, different metabolism
in humans and animals, and complete renal elimination
immediately after intake. However, the last criterion would
not apply to patients with CKD, and the possibility that BPA
may be an environmental uremic toxin requires further study.
7. BPA Toxicity in Experimental Animals
BPA can disrupt the development of newborn animals and
the immune system and may be carcinogenic. Evidence
from animal studies also shows alterations in adult animals
exposed to BPA resulting from estrogenic activity [41] or
causing liver damage [42], pancreatic damage [43], thyroid
disorders [44], or obesity [45].
There is direct evidence of neurological and endocrine
toxicity of BPA in rodents and zebra fish [53]. BPA can
influence the development of the embryonic zebra fish brain
including the hypothalamus, telencephalon, and preoptic
areas [54]. Exposure in utero or perinatally to BPA can
lead to permanent behavioral disorders in rodents, including
increased levels of aggression and anxiety and alterations in
learning, memory, exploration, and emotional responsive-
ness [55]. Several mouse studies concluded that maternal
exposure to low-dose BPA has long-term consequences on
neurobehavioral development [56] and neonatal exposure
to BPA can affect brain morphology and neuronal adult
phenotypes [57].
Exposure to BPA has persistent effects on body weight
and adiposity [58]. In rats, perinatal exposure to drinking
water containing 1mg/L BPA increased adipogenesis in
females at weaning [59].
The effects of neonatal BPA exposure on reproductive
organs in mice depended on the level of BPA, 2mg/kg
increased the adult prostate weight [60] and 10mg/kg
disrupted prostate development [61]. Exposure of rats to
10mg/kg BPA increased susceptibility to prostate carcino-
genesis in adults [62]. Male rats exposed to BPA have lower
sperm counts and testosterone levels with a significant effect
on fertility [53, 63].
8. BPA Toxicity in Humans
There are no studies linking serumBPA to disease in humans,
so it is unknown whether there are cutoff levels that may be
worrisome. Available studies have evaluated BPA exposure by
assessing urinary BPA [52].The evidence is observational and
no firm conclusions can be reached as to causality.
Exposure estimation based on urinary excretion may
not be valid in CKD [52]. In CKD it is unclear whether
low urinary excretion reflects low exposure or increased
retention. Exposure to BPA containers, such as bottles, for 7
days increases urinary BPA excretion in normal subjects from
1.2mcg/g creatinine to 2mcg/g [64].
In newborn infants greater exposure to BPA was asso-
ciated to altered behavior [47]. Prenatal exposure to BPA,
evaluated by maternal urinary BPA excretion (1–4mcg/L),
may be associatedwith behavioral disorders at 2 and 3 years of
age [65]. These values represent 1–8mcg for an average adult
of 70 kg. Comparatively, deleterious effects in mice required
from 60 to 300mcg BPA for a 20 g animal. Thus, the huge
dose used for animal experiments may not be relevant to the
human situation.
Several studies have linked BPA exposure to the devel-
opment of obesity, insulin resistance, metabolic syndrome,
diabetes, and atherosclerosis [48–50]. An epidemiological
association was observed between high urinary BPA and
cardiovascular disease. Each increase in urinary BPA of
4.5mcg/L was associated with a 13% increase in the incidence
of coronary heart disease in 10 years, although the signifi-
cance was lost after adjustment for traditional cardiovascular
risk factors [66]. The loss of the association when adjusted
for cardiovascular risk factors suggests that higher urinary
BPA may be related to high-risk habits and speaks against
a causal association between BPA and cardiovascular risk.
In healthy adult Americans’ urinary BPA levels >4mcg/L
were associated with a 50% increase in the prevalence of
hypertension compared with levels <1.5mcg/L [67]. Urinary
BPA levels >1.4mcg/L were associated with a 23% higher
risk of microalbuminuria than in healthy adults with levels
<0.5mcg/L [68, 69].
9. Accumulation of BPA in CKD
Published evidence on BPA in dialysis or CKD patients is
scarce and limited to the observation of increased blood
BPA levels. However, there is no evidence linking these
levels to any particular adverse effect or outcome, no cutoff
values have been defined, and no studies have shown that
decreasing the BPA levels has any impact on outcomes.


































Figure 2: Origin and metabolism of microbial (p-cresol) and environmental (BPA) phenols. Both can be absorbed in the digestive tract,
conjugated in the liver, and eliminated by the kidneys. BPA may also enter the blood from dialysis membranes.
The National Health and Nutrition Examination Survey
2003-6 (NHANES III) observed in 2573 patients a decrease
of urinary excretion of BPA with renal function impairment.
However, this was only significant in women and only when
the MDRD formula was used to estimate GFR: it was not
observed with CKD-EPI formula [70]. The meaning of these
data is uncertain: low urinary BPA excretion may reflect low
exposure to BPA (which would be desirable) or retention of
BPA by kidney disease (which would not be desirable). In
this sense, the lower levels of urinary BPA were associated
with lower risk of microalbuminuria [68] or hypertension
[60], suggesting that it may reflect less exposure to BPA. By
contrast increased serum BPAwith decreasing renal function
and higher levels in hemodialysis was observed in a smaller
study of 32 CKD patients [71], suggesting that BPA may
accumulate in CKD. One of the arguments by government
agencies for considering the safe use of BPA in the general
population is the almost complete urinary elimination of
the conjugated molecule [72]. The rapid urinary excretion
decreases the risks of exposure to BPA. For this reason,
studies on the potential consequences of BPA accumulation
in CKD patients are needed.
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BPA is found in the shell (polycarbonate) and mem-
branes of some commonly used dialyzers. The amount of
BPA in polyester polymer alloy (PEPA) is 12.2mcg/g, in
polysulfone 8 to 34.5mcg/g, in polycarbonate 47.2mcg/g, in
polymethylmethacrylate 0.008mcg/g, in cellulose triacetate
0.008mcg/g, and in cellulose 0.016mcg/g [71, 73].
BPA may be released from dialyzers, although values for
BPA release are lower than stipulated by health authorities.
Under experimental conditions release of BPA is higher
from dialysis filters perfused with blood (0.2 to 0.7 ng/mL)
than when perfused with saline (0.1 to 0.2 ng/mL) [74].
This difference has been attributed to the effect of blood
hydrophobic components such as lipids or lipoproteins. The
brand and sterilization method may also impact BPA release.
The highest BPA levels were released from steam-sterilized
polysulfone dialyzers with a polycarbonate shell (0.2 to
0.7 ng/mL) [75].The release of BPA is lowerwhen polysulfone
membranes are perfused with water (3.8–142 ng/module)
than when they are perfused with bovine serum (141–
2090 ng/module) [73].
What are the clinical consequences of these experimental
observations? Serum BPA is virtually undetectable when
renal function is normal. Mean BPA values in patients with
CKD were reported to be 0.23 ng/mL. Higher BPA values
were reported in patients dialyzed with first generation
polysulfone membranes (4.83 ± 1.94 ng/mL) and increased
postdialysis (6.62 ± 3.09 ng/mL), while lower values were
found in patients using second generation polysulfones [71].
In another cross-sectional study of 152 prevalent patients with
CKD, BPA plasma levels started to rise in patients with CKD
stage 3 and were >6-fold higher in hemodialysis patients
than in patients with CKD stage 5 not yet on dialys (10.0 ±
6.6 versus 1.6 ± 1.8 ng/mL; 𝑃 < 0.001). The very high
levels in hemodialysis patients may be related to inefficient
removal due to the high protein-bound fraction of plasma
BPA (74 ± 5%) [76]. In a randomized controlled study of
18 hemodialysis patients subjected successively to 4-week
dialysis with low-flux polysulfone, high-flux polysulfone, and
high-flux polyethersulfone, the plasma BPA concentrations
were very high in hemodialysis patients (range 9.1 ± 4.5–
12.0 ± 6.0 ng/mL versus ≤ 0.2 ± 0.1 ng/mL in normal renal
function controls; 𝑃 < 0.001) but did not change during
hemodialysis with any of the three dialyzers in the course of
a single treatment or over a period of 4 weeks [76].
A single study did not observe changes in BPA levels
during peritoneal dialysis in 4 patients [77].
10. Conclusions
BPA is an estrogenic endocrine disruptor molecule of phe-
nolic structure used in plastics, which has renal elimination,
and builds up when the glomerular filtration rate decreases.
Hemodialysis patients may be exposed to BPA from the
environment and also from hemodialysis filters. However,
to date no adverse effects have been linked to BPA in
dialysis patients. Furthermore it is unknown whether the
removal of BPA from these patients is associated with an
improved outcome. Studies should be designed to answer
these questions before BPA can be added to the list of
bona fide uremic toxins [78]. This requires validated and
standardized methods for measuring serum BPA as well as
careful prospective studies assessing predefined endpoints.
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